Estradiol Dosage
Medically reviewed by Drugs.com. Last updated on Dec 19, 2024.
Applies to the following strengths: valerate 40 mg/mL; valerate 10 mg/mL; valerate 20 mg/mL; cypionate 5 mg/mL; 0.05 mg/24 hr; 0.1 mg/24 hr; 0.025 mg/24 hours twice weekly; 0.05 mg/24 hours twice weekly; 0.075 mg/24 hours twice weekly; 0.1 mg/24 hours twice weekly; 0.52 mg/pump (0.06%); 0.75 mg/pump (0.06%); 0.025 mg/24 hours weekly; 0.0375 mg/24 hours twice weekly; 0.5 mg; 1 mg; 2 mg; 0.25 mg/packet (0.1%); 0.5 mg/packet (0.1%); 1 mg/packet (0.1%); 0.05 mg/24 hours weekly; 0.075 mg/24 hours weekly; 0.1 mg/24 hours weekly; 0.0375 mg/24 hours weekly; 0.06 mg/24 hours weekly; 1.5 mg; acetate 0.45 mg; acetate 0.9 mg; acetate 1.8 mg; 1.53 mg/spray; 0.75 mg/packet (0.1%); 1.25 mg/packet (0.1%); benzoate; valerate; 14 mcg/24 hours weekly; hemihydrate
Usual Adult Dose for:
- Postmenopausal Symptoms
- Atrophic Urethritis
- Atrophic Vaginitis
- Hypoestrogenism
- Oophorectomy
- Primary Ovarian Failure
- Breast Cancer-Palliative
- Prevention of Osteoporosis
- Prostate Cancer
Additional dosage information:
Usual Adult Dose for Postmenopausal Symptoms
ORAL TABLETS:
Initial dose: 1 to 2 mg orally once a day
- Adjust dose as necessary to control symptoms
- Administration should be cyclic (e.g., 3 weeks on, 1 week off)
TRANSDERMAL:
Transdermal Patch TWICE-weekly (Vivelle-Dot, Minivelle, Alora, Dotti, Lyllana):
- Initial dose: 0.0375 or 0.05 mg/24 hours applied topically twice a week; adjust dose based on clinical response
- Maintenance dose: 0.025 to 0.1 mg/24 hours applied topically twice a week
Transdermal Patch ONCE-weekly (Climara):
- Initial dose: 0.025 mg/24 hours applied topically once a week; adjust dose based on clinical response
- Maintenance dose: 0.025 to 0.1 mg/24 hours applied topically once a week
Transdermal 0.1% Gel Packets (Divigel):
- Initial dose: Apply 0.25 mg estradiol topically once a day to the skin of either the right or left upper thigh
- Adjust the dose as needed (packets available as estradiol 0.25, 0.5, 0.75, 1, and 1.25 mg)
- Maximum dose: 1.25 mg estradiol/day
Transdermal Metered-Dose Pump
- Initial dose (Elestrin): Apply 1 pump (0.52 mg estradiol) topically to upper arm once a day; dose adjustments can be made based on clinical response
- Recommended dose (Estrogel): Apply 1 pump (0.75 mg estradiol) topically once a day to arm
Transdermal Spray:
- Initial dose (Evamist): Apply 1 spray (1.53 mg) topically to the forearm once a day in the morning; adjust dose based on clinical response
- Maintenance dose: 1 to 3 sprays topically once a day
VAGINAL RING:
- Initial dose (Femring): Insert 1 ring intravaginally once every 90 days
- Therapy should generally be initiated with 0.05 mg estradiol/day; adjust dose based on clinical response; a second strength delivering estradiol 0.1 mg/day is available
PARENTERAL:
- Estradiol cypionate (Depo-estradiol): 1 to 5 mg IM every 3 to 4 weeks
- Estradiol valerate (Delestrogen): 10 to 20 mg IM every 4 weeks
Comments:
- When estrogen is prescribed for a postmenopausal woman with a uterus, a progestogen should be co-prescribed to reduce the risk of endometrial cancer; some hysterectomized women with a history of endometriosis may need a progestogen (i.e., residual endometrial implants post hysterectomy).
- Estrogen should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman; reevaluate periodically (e.g., every 3 to 6 months) as clinically appropriate to determine whether treatment is still necessary.
Uses: For the treatment of moderate to severe vasomotor symptoms associated with menopause
Usual Adult Dose for Atrophic Urethritis
ORAL TABLETS:
Initial dose: 1 to 2 mg orally once a day
- Adjust dose as necessary to control symptoms
- Administration should be cyclic (e.g., 3 weeks on, 1 week off)
TRANSDERMAL:
Transdermal Film/Patch TWICE-weekly (Vivelle-dot, Alora, Dotti):
- Initial dose: 0.0375 or 0.05 mg/24 hours applied topically twice a week; adjust dose based on clinical response
- Maintenance dose: 0.025 to 0.1 mg/24 hours applied topically twice a week
Transdermal Film/Patch ONCE-weekly (Climara):
- Initial dose: 0.025 mg/24 hours applied topically once a week; adjust dose based on clinical response
- Maintenance dose: 0.025 to 0.1 mg/24 hours applied topically once a week
Transdermal Metered-Dose Pump
- Recommended dose (Estrogel): Apply 1 pump (0.75 mg estradiol) topically once a day to arm
VAGINAL RING:
- Initial dose (Femring): Insert 1 ring intravaginally once every 90 days
- Therapy should generally be initiated at 0.05 mg estradiol/day; adjust dose based on clinical response; a 0.1 mg/day vaginal ring is also available
PARENTERAL:
- Estradiol cypionate (Depo-estradiol): 1 to 5 mg IM every 3 to 4 weeks
- Estradiol valerate (Delestrogen): 10 to 20 mg IM every 4 weeks
Comments:
- When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, first consider topical vaginal products.
- When estrogen is prescribed for a postmenopausal woman with a uterus, a progestogen should be co-prescribed to reduce the risk of endometrial cancer; some hysterectomized women with a history of endometriosis may need a progestogen (i.e., residual endometrial implants post hysterectomy).
- Use estrogen at the lowest effective dose and the shortest duration consistent with treatment goals and risks for the individual woman; reevaluate periodically as clinically appropriate to determine whether treatment is still necessary.
Use: For the treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause
Usual Adult Dose for Atrophic Vaginitis
ORAL TABLETS:
Initial dose: 1 to 2 mg orally once a day
- Adjust dose as necessary to control symptoms
- Administration should be cyclic (e.g., 3 weeks on, 1 week off)
TRANSDERMAL:
Transdermal Film/Patch TWICE-weekly (Vivelle-dot, Alora, Dotti):
- Initial dose: 0.0375 or 0.05 mg/24 hours applied topically twice a week; adjust dose based on clinical response
- Maintenance dose: 0.025 to 0.1 mg/24 hours applied topically twice a week
Transdermal Film/Patch ONCE-weekly (Climara):
- Initial dose: 0.025 mg/24 hours applied topically once a week; adjust dose based on clinical response
- Maintenance dose: 0.025 to 0.1 mg/24 hours applied topically once a week
Transdermal Metered-Dose Pump
- Recommended dose (Estrogel): Apply 1 pump (0.75 mg estradiol) topically once a day to arm
VAGINAL RING:
- Initial dose (Femring): Insert 1 ring intravaginally once every 90 days
- Therapy should generally be initiated at 0.05 mg estradiol/day; adjust dose based on clinical response; a 0.1 mg/day vaginal ring is also available
PARENTERAL:
- Estradiol cypionate (Depo-estradiol): 1 to 5 mg IM every 3 to 4 weeks
- Estradiol valerate (Delestrogen): 10 to 20 mg IM every 4 weeks
Comments:
- When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, first consider topical vaginal products.
- When estrogen is prescribed for a postmenopausal woman with a uterus, a progestogen should be co-prescribed to reduce the risk of endometrial cancer; some hysterectomized women with a history of endometriosis may need a progestogen (i.e., residual endometrial implants post hysterectomy).
- Use estrogen at the lowest effective dose and the shortest duration consistent with treatment goals and risks for the individual woman; reevaluate periodically as clinically appropriate to determine whether treatment is still necessary.
Use: For the treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause
Usual Adult Dose for Hypoestrogenism
ORAL TABLETS:
Initial dose: 1 to 2 mg orally once a day
- Adjust dose as necessary to control symptoms
TRANSDERMAL:
Transdermal Film/Patch TWICE-weekly (Vivelle-Dot, Alora, Dotti):
- Initial dose: 0.0375 or 0.05 mg/24 hours applied topically twice a week; adjust dose based on clinical response
- Maintenance dose: 0.025 to 0.1 mg/24 hours applied topically twice a week
Transdermal Film/Patch ONCE-weekly (Climara):
- Initial dose: 0.025 mg/24 hours applied topically once a week; adjust dose based on clinical response
- Maintenance dose: 0.025 to 0.1 mg/24 hours applied topically once a week
PARENTERAL:
- Estradiol cypionate (Depo-estradiol): 1.5 to 2 mg IM at monthly intervals for hypoestrogenism due to hypogonadism only
- Estradiol valerate (Delestrogen): 10 to 20 mg IM every 4 weeks
Comments:
- Adjust dose as needed to control symptoms; the minimal effective dose for maintenance therapy should be determined by titration.
Uses: For the treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure
Usual Adult Dose for Oophorectomy
ORAL TABLETS:
Initial dose: 1 to 2 mg orally once a day
- Adjust dose as necessary to control symptoms
TRANSDERMAL:
Transdermal Film/Patch TWICE-weekly (Vivelle-Dot, Alora, Dotti):
- Initial dose: 0.0375 or 0.05 mg/24 hours applied topically twice a week; adjust dose based on clinical response
- Maintenance dose: 0.025 to 0.1 mg/24 hours applied topically twice a week
Transdermal Film/Patch ONCE-weekly (Climara):
- Initial dose: 0.025 mg/24 hours applied topically once a week; adjust dose based on clinical response
- Maintenance dose: 0.025 to 0.1 mg/24 hours applied topically once a week
PARENTERAL:
- Estradiol cypionate (Depo-estradiol): 1.5 to 2 mg IM at monthly intervals for hypoestrogenism due to hypogonadism only
- Estradiol valerate (Delestrogen): 10 to 20 mg IM every 4 weeks
Comments:
- Adjust dose as needed to control symptoms; the minimal effective dose for maintenance therapy should be determined by titration.
Uses: For the treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure
Usual Adult Dose for Primary Ovarian Failure
ORAL TABLETS:
Initial dose: 1 to 2 mg orally once a day
- Adjust dose as necessary to control symptoms
TRANSDERMAL:
Transdermal Film/Patch TWICE-weekly (Vivelle-Dot, Alora, Dotti):
- Initial dose: 0.0375 or 0.05 mg/24 hours applied topically twice a week; adjust dose based on clinical response
- Maintenance dose: 0.025 to 0.1 mg/24 hours applied topically twice a week
Transdermal Film/Patch ONCE-weekly (Climara):
- Initial dose: 0.025 mg/24 hours applied topically once a week; adjust dose based on clinical response
- Maintenance dose: 0.025 to 0.1 mg/24 hours applied topically once a week
PARENTERAL:
- Estradiol cypionate (Depo-estradiol): 1.5 to 2 mg IM at monthly intervals for hypoestrogenism due to hypogonadism only
- Estradiol valerate (Delestrogen): 10 to 20 mg IM every 4 weeks
Comments:
- Adjust dose as needed to control symptoms; the minimal effective dose for maintenance therapy should be determined by titration.
Uses: For the treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure
Usual Adult Dose for Breast Cancer-Palliative
10 mg orally 3 times a day for at least 3 months
Comments:
- As a palliative treatment for breast cancer in appropriately selected women and men with metastatic disease.
Use: For treatment of breast cancer (palliation only).
Usual Adult Dose for Prevention of Osteoporosis
ORAL TABLETS: At least 0.5 orally once a day
- Use lowest effective dose; however, the lowest effective dose has not been determined.
TRANSDERMAL:
Transdermal Film/Patch TWICE-weekly (Vivelle-Dot, Minivelle, Alora, Dotti, Lyllana):
- Initial dose: 0.025 mg/24 hours applied topically twice a week
Transdermal Film/Patch ONCE-weekly:
- Climara: Initial dose: 0.025 mg/24 hours applied topically once a week
- Menostar: Initial dose: 0.014 mg/24 hours applied topically once a week
Comments:
- If estrogen is being used solely for postmenopausal osteoporosis prevention, first consider the use of non-estrogen medications; consider estrogen only for women at significant risk of osteoporosis.
- When estrogen is prescribed for a postmenopausal woman with a uterus, a progestogen should be co-prescribed to reduce the risk of endometrial cancer; some hysterectomized women with a history of endometriosis may need a progestogen (i.e., residual endometrial implants post hysterectomy).
- Use estrogen at the lowest effective dose and the shortest duration consistent with treatment goals and risks for the individual woman; reevaluate periodically as clinically appropriate to determine whether treatment is still necessary.
- According to some manufacturers, perform, bone mineral density measurements to assess efficacy and adjust dose as necessary. No studies have been conducted using an intermittent regimen.
Use: For the prevention of postmenopausal osteoporosis
Usual Adult Dose for Prostate Cancer
ORAL: 1 to 2 mg orally 3 times a day
PARENTERAL:
- Estradiol valerate (Delestrogen): 30 mg or more IM every 1 or 2 weeks
Use: For the treatment (palliation only) of advanced androgen-dependent prostate carcinoma
Renal Dose Adjustments
Use with caution in patients with renal dysfunction; estrogens may cause some degree of fluid retention
Liver Dose Adjustments
Contraindicated in patients with hepatic impairment or disease
Precautions
US BOXED WARNINGS: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, and BREAST CANCER - Prescribe estrogens, with or without progestogens, at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman:
Estrogen-Alone Therapy:
- ENDOMETRIAL CANCER: There is an increased risk of endometrial cancer in woman with a uterus using unopposed estrogens; adding a progestin has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Diagnostic measures, including directed or random endometrial sampling should be performed when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
- CARDIOVASCULAR DISORDERS and PROBABLE DEMENTIA: Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia. The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years) taking conjugated estrogen (CE; 0.625 mg/day) for 7.1 years, relative to placebo. The WHI-Memory Study (WHIMS) substudy reported an increased risk of developing probable dementia in postmenopausal women over 65 years taking CE (0.625 mg/day) for 5.2 years, relative to placebo; it is unknown if this applies to younger postmenopausal women. The only estrogen in the WHI studies was CE 0.625 mg/day. The relevance of findings to lower doses, other routes of administration, or other estrogen-alone products is unknown. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks to other products. Discuss the benefits and risks of estrogen-alone therapy with patients, taking into account their individual risk profiles.
Estrogen Plus Progestin Therapy:
- CARDIOVASCULAR DISORDERS and PROBABLE DEMENTIA: Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia. The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI) in postmenopausal women (50 to 79 years) taking daily CE 0.625 mg plus medroxyprogesterone (MPA; 2.5 mg) for 5.6 years, relative to placebo. The WHIMS estrogen plus progestin substudy reported an increased risk of developing probable dementia in postmenopausal women over 65 years taking daily CE 0.625 mg plus MPA 2.5 mg for 4 years, relative to placebo; it is unknown if this applies to younger postmenopausal women.
- BREAST CANCER: The WHI estrogen plus progestin substudy reported an increased risk of invasive breast cancer. The only estrogen-progestogen studied was once daily CE 0.625 mg plus MPA 2.5 mg and therefore, the relevance of these findings regarding adverse cardiovascular events, dementia and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is unknown. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss the benefits and risks of estrogen plus progestogen therapy with patients, taking into account their individual risk profiles.
CONTRAINDICATIONS:
- Undiagnosed abnormal genital bleeding
- Breast cancer, or history of breast cancer (unless treated for metastatic disease/palliative therapy)
- Estrogen dependent neoplasia
- Active, or a history of DVT or PE
- Active, or a history (within past year) of arterial thromboembolic disease (e.g. stroke or MI)
- Anaphylactic reaction or angioedema, or hypersensitivity to active substance or any of the product ingredients
- Hepatic impairment or disease
- Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
- Pregnancy (oral tablets)
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Due to a multitude of different products, the manufacturer product information should be consulted for brand specific administration instructions and storage; illustrations are often provided for further guidance.
PARENTERAL: IM administration only
- Delestrogen: Administer IM only into upper, outer quadrant of the gluteal muscle
- Depo-estradiol: Short-term cyclic administration is recommended for vasomotor symptoms
TRANSDERMAL: Apply to clean, dry, unbroken skin; wash hands after application; do not apply to breasts
- Patches/Film: Apply to clean, dry area of the lower abdomen (below the umbilicus) or upper quadrant of the buttock. Replace every 3 to 4 days, rotating the application sites. Administration (of Vivelle-Dot, Dotti) should be cyclic in women with an intact uterus, or continuous in women without a uterus.
- Estrogel: Prime canister before first use (depress pump 5 times); apply a thin layer over the entire arm on the inside and outside from wrist to shoulder.
- Elestrin: Prime pump before first use; apply onto skin in a thin layer; the recommended area of application is the upper arm to shoulder; allow gel to dry for at least 5 minutes before dressing; do not apply sunscreen to area for at least 25 minutes.
- Divigel: Apply entire contents of unit dose packet to skin of either the right or left upper thigh; application surface area should be about 5 by 7 inches; allow to dry before dressing, do not wash site within 1 hour
- Evamist: Pump should be primed by spraying 3 sprays with the cover on; the container should be held upright and vertical for spraying; sprays are applied to adjacent, non-overlapping areas on the inner surface of the forearm, starting near the elbow; allow to dry for approximately 2 minutes before dressing; the site should not be washed for at least 30 minutes.
VAGINAL RING:
- Femring: Insert as deeply as possible into the upper vagina; allow to remain in place for 90 days, then remove and replace with a new ring.
Storage requirements:
- Consult the manufacturer product information.
Reconstitution/preparation techniques:
- Parenteral products: Visually inspect for particulate matter and discoloration before administration. Warm or shake the vial to redissolve any crystals.
General:
- For women with an intact uterus: Studies have shown the addition of progestin for 10 or more days of an estrogen cycle, or daily with estrogen in a continuous regimen, result in a lower incidence of endometrial hyperplasia than estrogen alone. Endometrial hyperplasia may be a precursor to endometrial cancer, and adequate diagnostic measures, such as endometrial sampling, should be undertaken to rule out malignancy for undiagnosed persistent or recurring abnormal vaginal bleeding.
- There are possible risks associated with use of progestins and these risks should be considered.
- Estrogen therapy should be guided by goals of therapy and clinical response; the lowest effective dose should be used for the shortest duration consistent with treatment goals and risks for the individual woman.
- Patients should be reevaluated periodically as clinically appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is still necessary.
- Estradiol tablets may contain tartrazine (a synthetic colorant) which may cause allergic-type reactions, including bronchial asthma, in susceptible individuals such as those with aspirin hypersensitivity.
Monitoring:
- Endocrine: Thyroid function in women on thyroid replacement (during therapy)
- Other: Mammography (yearly during therapy, or with increased frequency as needed)
Patient advice:
- Patients should be instructed to read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
- Patients should be instructed to report vaginal bleeding to their healthcare provider as soon as possible.
- Patients should discuss with their healthcare provider the possible serious adverse reactions of therapy including cardiovascular disorders, malignant neoplasms, and possible dementia.
- For patients with an intact uterus, they should understand the benefit of concomitant progestin use.
- Patients of childbearing potential: Notify health care provider of a known/suspected pregnancy.
More about estradiol
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (590)
- Drug images
- Side effects
- Patient tips
- During pregnancy
- Support group
- Drug class: estrogens
- Breastfeeding
Patient resources
- Estradiol drug information
- Estradiol injection
- Estradiol topical
- Estradiol transdermal skin patch
- Estradiol vaginal
Other brands
Estrace, Estradiol Patch, Dotti, Estrogel, ... +18 more
Professional resources
- Estradiol (Systemic, Local) monograph
- Estradiol (FDA)
- Estradiol Film (FDA)
- Estradiol Valerate Injection (FDA)
Other brands
Estrace, Estradiol Patch, Dotti, Estrogel, ... +12 more
Related treatment guides
See also:
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Fosamax
Fosamax (alendronate) is used to treat or prevent postmenopausal osteoporosis and steroid-induced ...
Gemtesa
Gemtesa (vibegron) is used to treat overactive bladder symptoms (OAB) in adults or men taking ...
Myrbetriq
Myrbetriq (mirabegron) is used to treat overactive bladder with symptoms of frequent or urgent ...
Premarin
Premarin is used to treat symptoms of menopause such as hot flashes, and vaginal dryness. Learn ...
Medroxyprogesterone
Medroxyprogesterone (Provera) treats conditions such as absent or irregular menstrual periods, or ...
Solifenacin
Solifenacin (Vesicare) is used to treat overactive bladder symptoms such as frequent or urgent ...
Mirabegron
Mirabegron systemic is used for neurogenic detrusor overactivity, overactive bladder, urinary ...
Testosterone
Testosterone is used in men and boys to treat conditions caused by a lack of this hormone. Includes ...
Oxybutynin
Oxybutynin is used to treat symptoms of overactive bladder such as incontinence. Learn about side ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.